Abstract
Keshan disease (KD) is a novel cardiomyopathy of unclear cause which only occurred in some poor rural areas of China, characterized by obvious yearly and seasonal prevalence as well as vulnerability for self-sufficient farming population, killing hundreds of thousands of people over last century. Based on time course of onset and cardiac function of a suffering patient, KD is generally classified into four transformable types: acute type, sub-acute type, chronic type, and latent type. And their major clinical manifestations are cardiac dysfunction and arrhythmia.
KD was first recognized in medicine in the period when Japan invaded Northeast China. Since 1949, Chinese governments have made great efforts in fighting against KD epidemics, through broad social mobilization and engagement of local residents, especially deployment of substantial resources including money and medical teams to stem the outbreaks and save lives with combined measures. In the 1960s, Chinese investigators achieved multiple groundbreaking discoveries in the control and prevention of KD—several plausible etiological hypotheses and highly effective approaches for emergency rescue of critically ill patients by high-dose intravenous vitamin C therapy and for community-based primary prevention by selenium supplementation or balanced diet. Most importantly, since China’s open policy in 1978, the overall prevalence of KD has begun to decline dramatically thanks to rapid economic development in affected villages, reaching the lowest level ever and sustaining a steady state. Ultimately, we won the battle but at immense cost. Relevant sectors of governments have moved on, shifted from 1990 to focus on the disease surveillance and home care for heart failure, and believed that it would be completely eliminated following the implementation of poverty relief programs.
In this chapter, we provide basic knowledge on KD from perspectives of clinical medicine, pathology and epidemiology, and will particularly give emphasis on the major accomplishments and experiences worth spreading by reviewing its past control history.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Xu HC. A monument to the control of Keshan disease. In the Documentary of endemic disease prevention and treatment in Heilongjiang Province. Harbin: Helongjiang People’s Press; 1994.
Yu WH. Keshan disease and its control research in China. Beijing: China Environmental Science Press; 1987.
Sun DJ. Endemiology. Beijing: People’s Medical Publishing House; 2011.
Tan JA, An WY, Li RB. The geo-medical characteristics of Keshan disease. In: Keshan disease prevention and treatment in China: Chinese Environmental Sciences Press; 1987. p. 254–64.
Wang T, Hou J, Zhang LJ. National Keshan disease surveillance in 2007. Chin J Endemiol. 2008;27(4):412–5.
Sun SQ. Mysterious cause of Keshan disease: a medical puzzle for one hundred years. In: 10,000 Selected problems in science (medicine). Beijing: Science Press; 2011.
Xie JK. Engagement in the control and prevention of Keshan disease for 28 years along our own created path. Acta ademiae Medicinae Xi’an. 1984;5(4):476–81.
Xu GL. The effectiveness of sodium selenite on prevention of acute attacks of Keshan diseases. Chin Med J. 1979;92:471–6.
Yu WH. Keshan disease in China. Harbin: Heilongjiang Science and Technology Press; 2002.
Lin ZG. About the cause of Keshan disease. In: Symposium of national seminar on endemic disease control. Xi’an: Leadership Group Office of Shaanxi Provincial CPC Committee on Endemic Disease Control; 1962.
Zhou HH, Wang T. Progress in the etiological studies of Keshan disease. Chin J Endemiol. 2015;34(6):466–8.
Guo KD. Progress in the study of mycotoxin poisoning hypothesis on keshan disease in the past 30 years. Med Res Commun. 1986;15(10):289–94.
Yang JB, Yang QH. An etiological study on Keshan disease. Chin J Endemiol. 2000;19(5):350–5.
Xia DY. The diagnosis and treatment of acute Keshan disease. J Pract Med J. 1985;5(10):560–562, 535.
Clinical Group of Keshan Disease Research Laboratory, Jilin Medical University. Clinical manifestations of subacute Keshan disease. J Jilin Med Univ. 1976;8(3):19–28.
Xia DY. The procedure and method of diagnosis and differential diagnosis of Keshan disease. J Pract Intern Med. 1989;9(9):459–60.
The State Technology Supervision Bureau and the Ministry of Health of the People’s Republic of China. Criteria for diagnosis of Keshan disease (GB 17021-1997). National Standards of the People’s Republic of China. Standards Press of China; 1998. p. 1–3.
The Ministry of Health of the People’s Republic of China. Diagnosis of Keshan disease (WS/T 210-2011). Health Standards of the People’s Republic of China. Standards Press of China; 2011.
Gu BQ, Li CR, Shi DZ, Jia WZ, Guo SS. The study of cardiac pathological changes in Keshan diasease I. Basic pathological changes. J Harbin Med Univ. 1965;4(1):18–21, 31–4
Shi DZ, Gu BQ. The study of cardiac pathological changes in Keshan diasease III. The relationship between myocardial necrosis and coronary vessels. J Harbin Med Univ. 1965;4(1):28–30, 35
Gu BQ, Shi DZ, Jia WZ, Li CR, Guo SS. The study on cardiac pathological changes in Keshan diasease II. The type of cardiac pathological changes. J Harbin Med Univ. 1965;4(1):22–7, 31–4
Wang SC. Changing the way of thinking for establishing the therapy of high-dose vitamin C - in memory of the 60 anniversary of the discovery of Keshan disease and the 35 anniversary of the therapy of high-dose vitamin C founded. Bull Endem Dis. 1996;11(2):7–11.
Chen JS. Observations of the effect of sodium selenite in the prevention of Keshan diseases. Acta Nutrimenta Sin. 1982;4:243–9.
Wang T, Hou J, Li Q, Zhang LJ, Li XZ, Gao L, Pei JR, Deng J, et al. National Keshan disease surveillance in 2004. Chin J Endemiol. 2005;24(4):401–3.
Wang T, Hou J, Li Q. National Keshan disease surveillance in 2005. Chin J Endemiol. 2006;25(4):405–7.
Elliott P, Wartenberg D. Spatial epidemiology: current approaches and future challenges. Environ Health Perspect. 2004;112:998–1006.
Rothman KJ. Modern epidemiology. Boston: Little Brown; 1986.
Rothman KJ. Epidemiology, an introduction. Oxford: Oxford University Press; 2002.
Elwood M. Critical appraisal of epidemiological studies and clinical trials. Oxford: Oxford University Press; 2003.
Savitz DA. Interpreting epidemiologic evidence: strategies for study design and analysis. Oxford: Oxford University Press; 2003.
Ahrens W, Pigeot I, editors. Handbook of epidemiology. Berlin: Springer; 2005.
Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
Centers for Disease Control (CDC). CDC MMWR guidelines for evaluating surveillance systems. Morb Mortal Wkly Rep. 1988;37(Suppl 5):1–18. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001769.htm. Accessed 2 June 2012
Centers for Disease Control (CDC). Updated guidelines for evaluating public health surveillance systems: recommendations from the guidelines working group. MMWR Morb Mortal Wkly Rep. 2001;50(RR-13):13–25.
The Ministry of Health of the Peoples Republic of China. Protocol of national KD surveillance. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohjbyfkzj/s5874/200908/42374.htm. Accessed 1 June 2012.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd. and People's Medical Publishing House
About this chapter
Cite this chapter
Sun, D., Sun, S., Feng, H., Hou, J. (2019). Keshan Disease. In: Sun, D. (eds) Endemic Disease in China. Public Health in China, vol 2. Springer, Singapore. https://doi.org/10.1007/978-981-13-2529-8_6
Download citation
DOI: https://doi.org/10.1007/978-981-13-2529-8_6
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-2528-1
Online ISBN: 978-981-13-2529-8
eBook Packages: MedicineMedicine (R0)